According to this study, Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market size will reach US$ 569 million by 2031.

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size and Outlook 2025-31

According to this study, the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market size will reach US$ 569 million by 2031. ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia and can affect children and adults alike. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. LPI (LP Information) newest research report, the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Forecast looks at past sales and reviews total world Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics sales for 2025 through 2031. With Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics industry. This Insight Report provides a comprehensive analysis of the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics. This report presents a comprehensive overview, market shares, and growth opportunities of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Corticosteroids &nbsp;&nbsp;&nbsp; Intravenous Immunoglobulin (IVIG) &nbsp;&nbsp;&nbsp; Anti-D Immunoglobulin &nbsp;&nbsp;&nbsp; Thrombopoietin Receptor Agonists (TPO-RA) &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospitals &nbsp;&nbsp;&nbsp; Clinics &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Roch &nbsp;&nbsp;&nbsp; Amgen Inc &nbsp;&nbsp;&nbsp; Grifols Biologicals Inc. &nbsp;&nbsp;&nbsp; GlaxoSmithKline Plc

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2020-2031) &nbsp;2.1.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Type &nbsp;2.2.1 Corticosteroids &nbsp;2.2.2 Intravenous Immunoglobulin (IVIG) &nbsp;2.2.3 Anti-D Immunoglobulin &nbsp;2.2.4 Thrombopoietin Receptor Agonists (TPO-RA) &nbsp;2.2.5 Others &nbsp;2.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type &nbsp;2.3.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Market Share by Type (2020-2025) &nbsp;2.4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Application &nbsp;2.4.1 Hospitals &nbsp;2.4.2 Clinics &nbsp;2.4.3 Others &nbsp;2.5 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application &nbsp;2.5.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Market Share by Application (2020-2025) 3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Player &nbsp;3.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Market Share by Player &nbsp;3.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Player (2020-2025) &nbsp;3.1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Region &nbsp;4.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2020-2025) &nbsp;4.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth (2020-2025) &nbsp;4.4 APAC Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth (2020-2025) &nbsp;4.5 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2020-2025) &nbsp;5.2 Americas Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2020-2025) &nbsp;5.3 Americas Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2020-2025) &nbsp;6.2 APAC Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2020-2025) &nbsp;6.3 APAC Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2020-2025) &nbsp;7.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2020-2025) &nbsp;7.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Region (2020-2025) &nbsp;8.2 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast &nbsp;10.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast by Region (2026-2031) &nbsp;10.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.1.3 APAC Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.1.4 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.1.5 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.2 Americas Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.2.2 Canada Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.2.3 Mexico Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.2.4 Brazil Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.3 APAC Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast by Region (2026-2031) &nbsp;10.3.1 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast &nbsp;10.3.2 Japan Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.3.3 Korea Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.3.4 Southeast Asia Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.3.5 India Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.3.6 Australia Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.4 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.4.2 France Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.4.3 UK Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.4.4 Italy Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.4.5 Russia Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.5 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.5.2 South Africa Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.5.3 Israel Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.5.4 Turkey Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast &nbsp;10.6 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast by Type (2026-2031) &nbsp;10.7 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast 11 Key Players Analysis &nbsp;11.1 Roch &nbsp;11.1.1 Roch Company Information &nbsp;11.1.2 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Offered &nbsp;11.1.3 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Roch Main Business Overview &nbsp;11.1.5 Roch Latest Developments &nbsp;11.2 Amgen Inc &nbsp;11.2.1 Amgen Inc Company Information &nbsp;11.2.2 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Offered &nbsp;11.2.3 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Amgen Inc Main Business Overview &nbsp;11.2.5 Amgen Inc Latest Developments &nbsp;11.3 Grifols Biologicals Inc. &nbsp;11.3.1 Grifols Biologicals Inc. Company Information &nbsp;11.3.2 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Offered &nbsp;11.3.3 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Grifols Biologicals Inc. Main Business Overview &nbsp;11.3.5 Grifols Biologicals Inc. Latest Developments &nbsp;11.4 GlaxoSmithKline Plc &nbsp;11.4.1 GlaxoSmithKline Plc Company Information &nbsp;11.4.2 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Offered &nbsp;11.4.3 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 GlaxoSmithKline Plc Main Business Overview &nbsp;11.4.5 GlaxoSmithKline Plc Latest Developments 12 Research Findings and Conclusion

Report	Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Growth (Status and Outlook) 2025-2031
Selected License	Single ID:LPI23934

Buyer Information

Order Summary